Everolimus for astrocytomas in tuberous sclerosis - author's reply

Comment

David Neal Franz. Lancet. 2013.

. 2013 Apr 13;381(9874):1275.

doi: 10.1016/S0140-6736(13)60837-5.

No abstract available

Comment on

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.
Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Whittemore VH, Thiele EA, Ford JP, Shah G, Cauwel H, Lebwohl D, Sahmoud T, Jozwiak S. Franz DN, et al. Lancet. 2013 Jan 12;381(9861):125-32. doi: 10.1016/S0140-6736(12)61134-9. Epub 2012 Nov 14. Lancet. 2013. PMID: 23158522 Clinical Trial.
Everolimus for astrocytomas in tuberous sclerosis.
Mukherjee D, Sarmiento JM, Ly D, Nuno MA, Patil CG. Mukherjee D, et al. Lancet. 2013 Apr 13;381(9874):1274-5. doi: 10.1016/S0140-6736(13)60836-3. Lancet. 2013. PMID: 23582392 No abstract available.